Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease: Pitfalls and Promise
Research output: Contribution to journal › Article
The principal targets for anti-chemokine therapy in inflammatory bowel disease (IBD) have been the receptors CCR9 and CXCR3 and their respective ligands CCL25 and CXCL10. More recently CCR6 and its ligand CCL20 have also received attention; the expression of the latter in enterocytes being manipulated through Smad7 signalling. These pathways, selected based on their fundamental role in regulating mucosal immunity have led to the development of several therapeutic candidates that have been tested in early phase clinical trials with variable clinical efficacy. In this article, we appraise the status of chemokine-directed therapy in IBD, review recent developments and nominate future areas for therapeutic focus.
|Journal||Journal of Crohn's & Colitis|
|Early online date||23 Feb 2018|
|Publication status||Published - 22 Aug 2018|
- Eldelumab, Mongersen, Vercirnon